This study highlights the crucial contribution of BMDCs to enhancing antitumor immunity of the MUC1 DNA vaccine and provides supporting preclinical evidence for its tolerance-breaking efficacy in a clinically relevant mouse model of human colon cancer. This evidence concerns the gene MUC1 and colonic neoplasm.